Tag: Dovato

August 7, 2020 Off By Dino Mustafić

The FDA approved an expanded indication of ViiV Healthcare’s Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1 with no history of treatment failure or resistance to Dovato’s components.

July 5, 2019 Off

ViiV gets EC’s OK for HIV-1 infection drug Dovato

By Dino Mustafić

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, this week said that the European Commission has granted Marketing Authorisation for HIV-1 infection treatment, Dovato.